Suchergebnisse - "Oprea, Corina"

PubPharm (23)

1

Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation

enthalten in: Leukemia | 2023

von Ocio, E. | Perrot, A. | Bories, P. | +18

2

Isatuximab monotherapy in patients with refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma : Phase 2 study

enthalten in: Cancer medicine | 2022

von Boissel, N. | Chevallier, P. | Doronin, V. | +12

3

Isatuximab monotherapy in patients with refractory T‐acute lymphoblastic leukemia or T‐lymphoblastic lymphoma : Phase 2 study

enthalten in: Cancer Medicine | 2022

von Boissel, N. | Chevallier, P. | Doronin, V. | +12

4

COVID 19 - a new threat for smokers and vapers?

enthalten in: Pneumonologia | 2020

von Mihălţan, F. | Oprea, C. | Coşei, V. | +1

5

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

enthalten in: Leukemia | 2020

von Mikhael, J. | Richter, J. | Vij, R. | +16

6

Telemedicine During COVID 19 - A Useful Tool in COPD Patient Management

enthalten in: Medicină internă | 2020

von Mihălţan, F. | Oprea, C. | Coşei, V. | +2

7

Telemedicine During COVID 19 - A Useful Tool in COPD Patient Management

enthalten in: Medicină internă | 2020

von Mihălţan, F. | Oprea, C. | Coşei, V. | +2

8

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

enthalten in: European journal of cancer (Oxford, England : 1990) | 2020

von Pearson, A. | Rossig, C. | Lesa, G. | +42

9

ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients

enthalten in: European journal of cancer | March 2020

von Pearson, A. | Rossig, C. | Lesa, G. | +42

10

A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy

enthalten in: Haematologica | 2018

von Trnĕný, M. | Verhoef, G. | Dyer, M. | +18